Published online before print August 31, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
1 Correspondence: National Cancer Institute, 37 Convent Dr., Bldg. 37, Rm. 3044A, Bethesda, MD 20892, USA. E-mail: xw3u{at}nih.gov
Hepatocellular carcinoma (HCC) is a frequent malignancy worldwide with a high rate of metastasis. The hepatitis B and C viruses are considered major etiological factors associated with the development of HCC, particularly as a result of their induction of chronic inflammation. There is increasing evidence that the inflammatory process is inherently associated with many different cancer types, including HCC. Specifically, this review aims to cover evidence for the potential roles of cytokines, an important component of the immune system, in promoting HCC carcinogenesis and progression. A global summary of cytokine levels, functions, polymorphisms, and therapies with regard to HCC is presented. In particular, the role of proinflammatory Th1 and anti-inflammatory Th2 cytokine imbalances in the microenvironment of HCC patients with metastasis and the possible clinical significance of these findings are addressed. Overall, multiple studies, spanning many decades, have begun to elucidate the important role of cytokines in HCC.
Key Words: liver • inflammation • immune • metastasis • hepatitis
This article has been cited by other articles:
 |
|
 |
|
  C. Berasain, M. J. Perugorria, M. U. Latasa, J. Castillo, S. Goni, M. Santamaria, J. Prieto, and M. A. Avila The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer Experimental Biology and Medicine, July 1, 2009; 234(7): 713 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Enewold, L. E. Mechanic, E. D. Bowman, Y.-L. Zheng, Z. Yu, G. Trivers, A. J. Alberg, and C. C. Harris Serum Concentrations of Cytokines and Lung Cancer Survival in African Americans and Caucasians Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 215 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sakai, M. Honda, H. Fujinaga, I. Tatsumi, E. Mizukoshi, Y. Nakamoto, and S. Kaneko Common Transcriptional Signature of Tumor-Infiltrating Mononuclear Inflammatory Cells and Peripheral Blood Mononuclear Cells in Hepatocellular Carcinoma Patients Cancer Res., December 15, 2008; 68(24): 10267 - 10279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Umannova, J. Zatloukalova, M. Machala, P. Krcmar, Z. Majkova, B. Hennig, A. Kozubik, and J. Vondracek Tumor Necrosis Factor-{alpha} Modulates Effects of Aryl Hydrocarbon Receptor Ligands on Cell Proliferation and Expression of Cytochrome P450 Enzymes in Rat Liver "Stem-Like" Cells Toxicol. Sci., September 1, 2007; 99(1): 79 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ozaki, H. Zhang, T. Mizuta, Y. Ide, Y. Eguchi, T. Yasutake, T. Sakamaki, R. G. Pestell, and K. Yamamoto Menatetrenone, a Vitamin K2 Analogue, Inhibits Hepatocellular Carcinoma Cell Growth by Suppressing Cyclin D1 Expression through Inhibition of Nuclear Factor {kappa}B Activation Clin. Cancer Res., April 1, 2007; 13(7): 2236 - 2245. [Abstract] [Full Text] [PDF]
|
|
